Read more

August 24, 2023
1 min read
Save

Top in women’s health: Restrictions on abortion pill; reduction in cesarean births

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The 5th U.S. Circuit Court of Appeals has ruled to roll back mifepristone regulations, ending availability via telehealth or mail. However, these restrictions will not go into effect unless they are upheld by the U.S. Supreme Court.

“Medication abortion using mifepristone is safe and effective. This is a fact, based on hundreds of medical studies, vast amounts of data amassed over the course of 2 decades and millions of uses of mifepristone for medication abortion,” Molly Meegan, JD, chief legal officer and general counsel for the American College of Obstetricians and Gynecologists, told Healio.

gavel_judge
The 5th U.S. Circuit Court of Appeals has ruled to roll back mifepristone regulations, ending availability via telehealth or mail. However, these restrictions will not go into effect unless they are upheld by the U.S. Supreme Court. Image source: Adobe Stock

It was the top story in women’s health last week.

The second top story was about a study that showed an increase in 39-week labor induction rates and a decrease in cesarean births after the ARRIVE trial was published in 2018.

Read these and more top stories in women’s health below:

Appeals court rules on restrictions to mifepristone abortion pill availability

The 5th U.S. Circuit Court of Appeals ruled on restrictions on the abortion drug mifepristone, but this ruling will not go into effect unless it is upheld by the U.S. Supreme Court. Read more.

ARRIVE trial linked to increased labor induction rates, reduced cesarean births

Publication of the ARRIVE trial was linked to a rise in 39-week labor induction rates and a decrease in cesarean birth rates among low-risk nulliparous women, according to a research letter published in JAMA Network Open. Read more.

Little regret, high satisfaction years after gender-affirming mastectomy

Individuals who underwent gender-affirming mastectomy reported low rates of regret and high levels of satisfaction more than 2 years after surgery, according to a cross-sectional survey study published in JAMA Surgery. Read more.

‘Break the silence’ surrounding menstruation stigma to lessen inequities

Menstrual inequity is experienced worldwide, even in the U.S., where stigmas surrounding menstruation continue affecting all forms of menstrual inequities such as period poverty, access issues and legal issues, according to experts. Read more.

Low perinatal risk with term pregnancies conceived with infertility treatment

Delivery at 39 weeks gestation among pregnancies conceived with infertility treatment was associated with the lowest perinatal risk when comparing delivery risk at a given vs. subsequent gestational week, researchers reported. Read more.